Pasithea Therapeutics Corp Financials
This page shows Pasithea Therapeutics Corp (KTTAW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Pasithea Therapeutics Corp passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Pasithea Therapeutics Corp generates $1.00 in operating cash flow (-$13.9M OCF vs -$13.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Pasithea Therapeutics Corp's EBITDA was -$14.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.8% from the prior year.
Pasithea Therapeutics Corp reported -$13.9M in net income in fiscal year 2024. This represents an increase of 12.9% from the prior year.
Pasithea Therapeutics Corp earned $-12.69 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 2921.4% from the prior year.
Pasithea Therapeutics Corp held $6.9M in cash against $0 in long-term debt as of fiscal year 2024.
Pasithea Therapeutics Corp had 1M shares outstanding in fiscal year 2024. This represents an increase of 33.9% from the prior year.
Pasithea Therapeutics Corp invested $7.2M in research and development in fiscal year 2024. This represents a decrease of 11.1% from the prior year.
KTTAW Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $241K+10.1% | $219K+1509.7% | $14K-0.6% | $14K |
| Cost of Revenue | N/A | N/A | N/A | N/A | -$1K-101.5% | $86K+472.6% | $15K+16.7% | $13K |
| Gross Profit | N/A | N/A | N/A | N/A | $242K+83.2% | $132K+8793.6% | -$2K-310.8% | $721 |
| R&D Expenses | $1.4M-14.1% | $1.6M | N/A | $1.6M | N/A | $1.3M | N/A | N/A |
| SG&A Expenses | $1.8M+23.1% | $1.4M | N/A | $2.2M-18.5% | $2.7M+3.1% | $2.6M-1.3% | $2.6M+25.6% | $2.1M |
| Operating Income | -$3.1M-3.5% | -$3.0M | N/A | -$3.8M+6.3% | -$4.0M-4.9% | -$3.9M-47.6% | -$2.6M-25.6% | -$2.1M |
| Interest Expense | N/A | N/A | N/A | -$117K | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.0M-1.3% | -$3.0M | N/A | -$3.6M+29.4% | -$5.1M-11.6% | -$4.6M-72.5% | -$2.7M-68.9% | -$1.6M |
| EPS (Diluted) | $-0.41 | $-2.87 | N/A | $0.00 | $-1.72 | $-0.01+50.0% | $-0.02-100.0% | $-0.01 |
KTTAW Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.6M-15.2% | $16.1M-38.5% | $26.1M-14.8% | $30.7M-32.1% | $45.2M-8.9% | $49.6M-6.4% | $53.0M+3.8% | $51.1M |
| Current Assets | $5.5M-25.0% | $7.4M-55.9% | $16.7M-19.6% | $20.8M-39.0% | $34.1M-23.4% | $44.5M-8.5% | $48.6M-4.6% | $50.9M |
| Cash & Equivalents | $4.1M-40.4% | $6.9M-57.6% | $16.3M-16.6% | $19.6M-40.8% | $33.1M-22.0% | $42.4M-11.6% | $47.9M-4.7% | $50.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $1.3M0.0% | $1.3M0.0% | $1.3M0.0% | $1.3M0.0% | $1.3M-67.2% | $3.9M+0.5% | $3.8M | N/A |
| Total Liabilities | $1.4M+11.1% | $1.3M-52.8% | $2.7M+19.0% | $2.3M-14.8% | $2.7M-4.9% | $2.8M+81.4% | $1.6M+41.1% | $1.1M |
| Current Liabilities | $1.4M+23.0% | $1.1M-57.5% | $2.6M+28.9% | $2.0M+8.9% | $1.9M+24.0% | $1.5M+59.3% | $950K+119.1% | $434K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $12.2M-17.4% | $14.8M-36.8% | $23.4M-17.5% | $28.4M-33.2% | $42.5M-9.2% | $46.8M-8.8% | $51.3M+2.7% | $50.0M |
| Retained Earnings | -$59.9M-20.8% | -$49.6M-40.4% | -$35.3M-16.7% | -$30.3M-56.4% | -$19.4M-75.4% | -$11.0M-71.1% | -$6.4M-70.2% | -$3.8M |
KTTAW Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M-18.3% | -$2.4M+25.8% | -$3.3M-1.7% | -$3.2M+44.7% | -$5.9M-26.6% | -$4.6M-196.2% | -$1.6M+38.3% | -$2.5M |
| Capital Expenditures | N/A | N/A | -$36+99.8% | -$23K-124.4% | $93K+1590.2% | $5K-20.9% | $7K+255.7% | $2K |
| Free Cash Flow | N/A | N/A | -$3.3M-1.0% | -$3.3M+45.2% | -$5.9M-28.5% | -$4.6M-195.3% | -$1.6M+38.0% | -$2.5M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$1.8M-662.1% | -$230K-694.7% | $39K+134.0% | -$114K |
| Financing Cash Flow | -$116K | N/A | N/A | -$3.9M | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | $0 | N/A | N/A | N/A | N/A | N/A |
KTTAW Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 60.5%+71.6pp | -11.2%-16.5pp | 5.3% |
| Operating Margin | N/A | N/A | N/A | N/A | -1679.5%+84.2pp | -1763.8%+17465.7pp | -19229.5%-4008.5pp | -15220.9% |
| Net Margin | N/A | N/A | N/A | N/A | -2126.1%-28.2pp | -2097.9%+17476.5pp | -19574.4%-8048.2pp | -11526.1% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -22.3%-6.2pp | -16.1% | N/A | -11.8%-0.5pp | -11.3%-2.1pp | -9.2%-4.2pp | -5.0%-1.9pp | -3.1% |
| Current Ratio | 4.02-2.6 | 6.58+0.2 | 6.34-3.8 | 10.16-8.0 | 18.15-11.2 | 29.37-21.8 | 51.17-66.3 | 117.48 |
| Debt-to-Equity | 0.12+0.0 | 0.09-0.0 | 0.12+0.0 | 0.08+0.0 | 0.060.0 | 0.06+0.0 | 0.030.0 | 0.02 |
| FCF Margin | N/A | N/A | N/A | N/A | -2469.9%-353.3pp | -2116.6%+9421.9pp | -11538.5%+6981.2pp | -18519.8% |
Similar Companies
Frequently Asked Questions
Is Pasithea Therapeutics Corp profitable?
No, Pasithea Therapeutics Corp (KTTAW) reported a net income of -$13.9M in fiscal year 2024.
What is Pasithea Therapeutics Corp's earnings per share (EPS)?
Pasithea Therapeutics Corp (KTTAW) reported diluted earnings per share of $-12.69 for fiscal year 2024. This represents a -2921.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Pasithea Therapeutics Corp's EBITDA?
Pasithea Therapeutics Corp (KTTAW) had EBITDA of -$14.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Pasithea Therapeutics Corp's operating cash flow?
Pasithea Therapeutics Corp (KTTAW) generated -$13.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Pasithea Therapeutics Corp's total assets?
Pasithea Therapeutics Corp (KTTAW) had $16.1M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Pasithea Therapeutics Corp spend on research and development?
Pasithea Therapeutics Corp (KTTAW) invested $7.2M in research and development during fiscal year 2024.
How many shares does Pasithea Therapeutics Corp have outstanding?
Pasithea Therapeutics Corp (KTTAW) had 1M shares outstanding as of fiscal year 2024.
What is Pasithea Therapeutics Corp's current ratio?
Pasithea Therapeutics Corp (KTTAW) had a current ratio of 6.58 as of fiscal year 2024, which is generally considered healthy.
What is Pasithea Therapeutics Corp's debt-to-equity ratio?
Pasithea Therapeutics Corp (KTTAW) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Pasithea Therapeutics Corp's return on assets (ROA)?
Pasithea Therapeutics Corp (KTTAW) had a return on assets of -86.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Pasithea Therapeutics Corp's cash runway?
Based on fiscal year 2024 data, Pasithea Therapeutics Corp (KTTAW) had $6.9M in cash against an annual operating cash burn of $13.9M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Pasithea Therapeutics Corp's Piotroski F-Score?
Pasithea Therapeutics Corp (KTTAW) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Pasithea Therapeutics Corp's earnings high quality?
Pasithea Therapeutics Corp (KTTAW) has an earnings quality ratio of 1.00x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.